- Home
- PHVS vs SMR Comparison
PHVS vs SMR Comparison
Compare PHVS & SMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- SMR
- Stock Information
- Founded
- PHVS 2015
- SMR 2007
- Country
- PHVS Netherlands
- SMR United States
- Employees
- PHVS N/A
- SMR N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- SMR Electrical Products
- Sector
- PHVS Health Care
- SMR Industrials
- Exchange
- PHVS Nasdaq
- SMR Nasdaq
- Market Cap
- PHVS 1.0B
- SMR N/A
- IPO Year
- PHVS 2021
- SMR N/A
- Fundamental
- Price
- PHVS $18.56
- SMR $17.63
- Analyst Decision
- PHVS Strong Buy
- SMR Buy
- Analyst Count
- PHVS 5
- SMR 5
- Target Price
- PHVS $40.60
- SMR $11.50
- AVG Volume (30 Days)
- PHVS 73.1K
- SMR 8.8M
- Earning Date
- PHVS 11-13-2024
- SMR 11-07-2024
- Dividend Yield
- PHVS N/A
- SMR N/A
- EPS Growth
- PHVS N/A
- SMR N/A
- EPS
- PHVS N/A
- SMR N/A
- Revenue
- PHVS N/A
- SMR $7,381,000.00
- Revenue This Year
- PHVS N/A
- SMR N/A
- Revenue Next Year
- PHVS N/A
- SMR $278.07
- P/E Ratio
- PHVS N/A
- SMR N/A
- Revenue Growth
- PHVS N/A
- SMR N/A
- 52 Week Low
- PHVS $15.37
- SMR $1.88
- 52 Week High
- PHVS $33.00
- SMR $32.30
- Technical
- Relative Strength Index (RSI)
- PHVS 51.83
- SMR 40.00
- Support Level
- PHVS $18.18
- SMR $17.36
- Resistance Level
- PHVS $19.88
- SMR $22.35
- Average True Range (ATR)
- PHVS 1.11
- SMR 2.10
- MACD
- PHVS 0.17
- SMR -0.39
- Stochastic Oscillator
- PHVS 76.86
- SMR 17.32
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.